Rheumatology International

, Volume 32, Issue 9, pp 2623–2627 | Cite as

Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases

  • Steffan W. Schulz
  • Max Shenin
  • Amy Mehta
  • Amal Kebede
  • Marshall Fluerant
  • Chris T. Derk
Original Article

Abstract

To describe and compare the diagnosis, demographics and management of systemic lupus erythematosus (SLE) related versus idiopathic acute transverse myelitis during the initial presentation of the disease. We undertook a chart review of the hospital records of patients admitted to our hospital from 1994 until 2007 and had the diagnosis of SLE related and idiopathic acute transverse myelitis. Demographics, laboratory and imaging studies, diagnosis and treatment were recorded in both groups and analyzed in a case control fashion. We identified 15 patients with SLE-related acute transverse myelitis (SLE-ATM) and 39 idiopathic (I-ATM) cases between 1994 and 2007. Patients with SLE were more likely to be African American, have CNS demyelinating lesions on MRI, a high IgG% on their CSF analysis and a higher sedimentation rate on presentation. Treatment with high-dose steroids was instituted in both groups of patients, though SLE patients had a longer hospital stay by an average of 5 days. SLE-ATM patients were more likely to be African American as compared to I-ATM patients, have CNS demyelinating lesions on MRI, a high IgG% on CSF analysis and a higher sedimentation rate on presentation. The hospital stay for SLE patients was 5 days longer than the idiopathic patients. This study underlines the importance of early diagnosis of patients who develop ATM related to SLE.

Keywords

Transverse myelitis Myelitis Autoimmunity Systemic lupus Sjogren’s syndrome Sarcoidosis 

References

  1. 1.
    Krishnan C, Kerr D (2005) Idiopathic transverse myelitis. Arch Neurol 62:1011–1013PubMedCrossRefGoogle Scholar
  2. 2.
    Kovacs B, Lafferty T, Brent L et al (2000) Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 59:120–124PubMedCrossRefGoogle Scholar
  3. 3.
    Berman M, Feldman S, Alter M et al (1981) Acute tranverse myelitis: incidence and etiologic considerations. Neurology 31:966–971PubMedCrossRefGoogle Scholar
  4. 4.
    Kaplin AI, Krsishnan C, Deshpande DM et al (2005) Diagnosis and management of acute myelopathies. Neurologist 11(1):2–18PubMedCrossRefGoogle Scholar
  5. 5.
    de Seze J, Stojkovic T, Breteau G et al (2001) Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain 124:1509–1521PubMedCrossRefGoogle Scholar
  6. 6.
    Piper PG (1953) Disseminated lupus erythematosus with involvement of the spinal cord. JAMA 153:215–217CrossRefGoogle Scholar
  7. 7.
    Adrianakos AA, Duffy J, Suzuki M et al (1975) Tranverse myelitis in systemic lupus erythematosus: report of three cases and review of the literatura. Ann Intern Med 83:616–624Google Scholar
  8. 8.
    Nakano I, Mannen T, Mizutani T et al (1989) Peripheral white matter lesions of the spinal cord with changes in small arachnoid arteries in systemic lupus erythematosus. Clin Neuropathol 8:102–108PubMedGoogle Scholar
  9. 9.
    Weil MH (1955) Diseeminated lupus erythematsosus with massive hemorrhagic manifestations and paraplegia. Lancet 75:353–360Google Scholar
  10. 10.
    Ayala L, Barber DB, Lomba MR et al (2000) Intramedullary sarcoidosis presenting as incomplete paraplegia: case report and literature review. J Spinal Cord Med 23:96–99PubMedGoogle Scholar
  11. 11.
    Hummers LK, Krishnan C, Casciola-Rosen L et al (2004) Recurrent transverse myelitis associates with anti-ro (SSA) autoantibodies. Neurology 62:147–149PubMedCrossRefGoogle Scholar
  12. 12.
    D’Cruz D, Mellor-Pita S, Joven B et al (2004) Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 31:280–285PubMedGoogle Scholar
  13. 13.
    Lu X, Gu Y, Wang Y et al (2008) Prognostic factors of lupus myelopathy. Lupus 17:323–328PubMedCrossRefGoogle Scholar
  14. 14.
    Deodhar AA, Hochenedel T, Bennett RM (1999) Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis. J Rheumatol 26:446–449PubMedGoogle Scholar
  15. 15.
    Tellez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RD et al (2001) Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging for six cases. Lupus 10:851–856PubMedCrossRefGoogle Scholar
  16. 16.
    Heinlein AC, Gertner E (2007) Marked inflammation in catastrophic longitudinal myelitis associated with systemic lupus erythematosus. Lupus 16:823–826PubMedCrossRefGoogle Scholar
  17. 17.
    Chan KF, Boey ML (1996) Transverse myelopathy in SLE: clinical features and functional outcomes. Lupus 5:294–299PubMedCrossRefGoogle Scholar
  18. 18.
    Lavalle C, Pizzaro S, Prenkand C et al (1990) Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 17:34–37PubMedGoogle Scholar
  19. 19.
    Barile L, Lavalle C (1992) Transverse myelitis in systemic lupus erythematosus—the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 19:370–372PubMedGoogle Scholar
  20. 20.
    Propper DJ, Bucknall RC (1989) Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 48:512–515PubMedCrossRefGoogle Scholar
  21. 21.
    Boumpas DT, Patronas NJ, Dalakas MC et al (1990) Acute transverse myelitis in systemic lupus erythematosus: clinical and magnetic resonance imaging and review of the literature. J Rheumatol 17:89–92PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Steffan W. Schulz
    • 1
  • Max Shenin
    • 1
  • Amy Mehta
    • 1
  • Amal Kebede
    • 1
  • Marshall Fluerant
    • 1
  • Chris T. Derk
    • 2
  1. 1.Division of RheumatologyThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Division of RheumatologyUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations